Our team is focused on bringing breakthrough immunotherapies in unmet medical needs for cancer patients. Check our work!
Location: France
Total raised: $19.88M
Investors 1
| Date | Name | Website |
| 10.07.2026 | SPRIM Glob... | sprim.net |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.01.2026 | Series A | $19.88M | - |
Mentions in press and media 9
| Date | Title | Description |
| 17.03.2026 | German BioTech iDEL Therapeutics lands €9 million to develop cancer therapeutics platform | Dortmund-based iDEL Therapeutics announced the closing of a €9 million Seed financing, to develop a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells. The financing was led by BiomedVC with particip... |
| 23.01.2026 | ErVimmune Unlocks €17M for Groundbreaking Cancer Vaccine Trials | ErVimmune, a Lyon-based biotech, secured €17 million in Series A funding. This pivotal investment propels its innovative off-the-shelf cancer vaccine, ErVac01, into human clinical trials. The company pioneers therapeutic vaccines targeting ... |
| 21.01.2026 | Atlas Invest Raises $25M in Funding | Atlas Invest, a NYC-based company which specializes in commercial real estate lending, raised a $25M facility. The round was led by BlackRock. The facility followed its recent $11M funding round. The company intends to use the funds to expa... |
| 21.01.2026 | ErVimmune Raises €17M in Series A First Closing | ErVimmune, a Lyon, France-based biotechnology company developing new therapeutic vaccines, raised €17M in Series A funding. Backers included Seventure Partners and SPRIM Global Investments. The company intends to use the funds to further en... |
| 21.01.2026 | French BioTech company ErVimmune raises €17 million to tackle hard-to-treat cancers | ErVimmune, a BioTech company out of Lyon developing cancer vaccines and cell therapies that target ‘cold tumors’ – cancers that do not respond to current immunotherapies – today announces the first closing of its €17 million ($19.8 million)... |
| 21.01.2026 | ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate | ErVimmune, a biotechnology company developing next-generation therapeutic vaccines targeting new families of ‘unconventional’ tumor antigens derived from human endogenous... |
| 21.01.2026 | ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate | Next-generation therapeutic vaccines company also welcomes industry veteran Eric Halioua to board, as executive chairman. Lead candidate ErVac01 is a cancer vaccine targeting novel tumor antigens derived from human endogenous retroviruses. ... |
| 21.01.2026 | ErVimmune: €17 Million Series A First Close To Advance Off-The-Shelf Cancer Vaccine Into The Clinic | ErVimmune, a Lyon, France-based biotechnology company developing next-generation therapeutic cancer vaccines targeting “unconventional” tumor antigens derived from human endogenous retroviruses (HERVs), has raised €17 million ($19.8 million... |
| - | ErVimmune | “Our team is focused on bringing breakthrough immunotherapies in unmet medical needs for cancer patients. Check our work!” |